<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491075</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0516</org_study_id>
    <nct_id>NCT00491075</nct_id>
  </id_info>
  <brief_title>Pemetrexed Plus Gemcitabine in Renal Cell Cancer</brief_title>
  <official_title>Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Advanced Non-Clear Cell Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  To determine the clinical activity of Pemetrexed + Gemcitabine in non-clear cell renal
           cell cancer (RCC). Clinical activity will take into account response rate and
           progression free survival (PFS).

      Secondary Objectives:

        -  To determine the toxicity of Pemetrexed + Gemcitabine in non-clear cell RCC.

        -  To estimate the survival rate of patients with non-clear cell RCC treated with this
           combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pemetrexed is a chemotherapy drug that is used to treat cancer. It is given intravenously (by
      IV--through a vein in your arm). It interferes with cell reproduction.

      Gemcitabine is a cancer-fighting (chemotherapy) drug that is given by IV. It interferes with
      the growth of cells and is used to treat cancer.

      Dexamethasone has many different medical uses. It is used to treat cancer, nausea, vomiting,
      inflammation, allergic reactions, and many other conditions. In this study, it is being given
      to prevent rashes.

      Folic acid and Vitamin B12 are vitamins given to prevent serious side effects which can occur
      with chemotherapy. These side effects include diarrhea and a decrease in you red blood cells,
      white blood cells, and your blood platelets.

      You will be required to take folic acid and vitamin B12. You will take folic acid, by mouth,
      daily beginning about 1 week before the first dose of Pemetrexed. You will continue to take
      it daily until 3 weeks after the last dose of chemotherapy. Vitamin B12 will be given as an
      injection into your muscle about 1 to 2 weeks before your first dose of Pemetrexed. You will
      have injections of vitamin B12 about every 9 weeks until 3 weeks after your last dose of
      chemotherapy.

      During treatment, you will be given Pemetrexed by IV for 10 minutes, followed by Gemcitabine
      by IV for 30 minutes on Day 1 of each 2-week study &quot;cycle.&quot;

      You will take Dexamethasone tablets by mouth, 2 times a day on the day before, the day of,
      and the day after each dose of Pemetrexed. Dexamethasone is taken to prevent rashes. If you
      could not or did not take Dexamethasone the day before and/or the day of Pemetrexed, you may
      be given Dexamethasone by IV over 20 minutes, 30 minutes before the infusion of Pemetrexed.

      You will have blood samples (about 4 teaspoons) drawn every week to test your bone marrow.
      You will have blood samples (about 1 teaspoon) drawn every 2 weeks to make sure that your
      kidneys and liver are working well. You will have a physical exam every 2 weeks before you
      receive chemotherapy. You will also be asked about any medications you have been taking since
      your last visit.

      Once every 8 weeks or after 4 cycles of treatment, you will have the tumor(s) measured using
      standard of care imaging which may include a CT scan, MRI, or a bone scan.

      You will be treated for as long as you are benefiting from the therapy. You will continue to
      receive treatment unless your tumor grows, intolerable side effects occur, or you develop
      another illness that prevents you from continuing with the therapy. You may also be taken off
      study if you fail to comply with the study requirements. If you are taken off study for any
      reason, you and your doctor will discuss other treatment options at that time.

      If you are taken off study, you will be asked to have the same scans as before, a physical
      exam, and routine blood (about 4 teaspoons). You will be contacted every 3 months after being
      off study, to get an update on your health status.

      This is an investigational study. Pemetrexed and Gemcitabine are FDA approved and
      commercially available. About 40 patients will take part in this study. All will be enrolled
      at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed early for poor accrual.
  </why_stopped>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response</measure>
    <time_frame>Baseline to 8 weeks (after 4 cycles) protocol response at 16 weeks</time_frame>
    <description>Number of participants with complete or partial response. Response Evaluation Criteria in Solid Tumors (RECIST) of Complete Response: disappearance all target lesions; Partial Response: &gt;30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease: &gt;20% increase sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1 or &gt; new lesions; Stable Disease: Insufficient shrinkage for partial response, or insufficient increase for progressive disease, reference smallest sum LD since treatment started.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pemetrexed + Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m^2 IV Over 10 Minutes on Day 1.</description>
    <arm_group_label>Pemetrexed + Gemcitabine</arm_group_label>
    <other_name>LY231514</other_name>
    <other_name>Alimta</other_name>
    <other_name>MTA</other_name>
    <other_name>Multitargeted Antifolate</other_name>
    <other_name>NSC-698037</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1500 mg/m^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.</description>
    <arm_group_label>Pemetrexed + Gemcitabine</arm_group_label>
    <other_name>Gemcitabine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed advanced non-clear cell
             RCC. Patients with locally recurrent disease are eligible. Patients with locally
             advanced unresectable RCC should have measurable metastatic disease to be eligible for
             the protocol. Patients with bilateral renal cancer are eligible as long as both
             cancers are of non-clear cell type and patients have metastatic disease.

          -  Patients must have measurable disease.

          -  Patients with previously treated or untreated, non-threatening brain metastasis are
             eligible. For previously treated patients, prior whole brain radiation therapy or
             stereotactic radiosurgery must be &gt; 3 months from initiation of current therapy and
             there can be no plans for concurrent radiation while on this study. Patients who had
             surgical resection for brain metastasis are eligible to enroll after they recover from
             surgery.

          -  Life expectancy &gt; 8 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Patients must have adequate organ and marrow function as defined below: (1) Hemoglobin
             &gt;/= 9g/dl; (2) absolute neutrophil count &gt;/= 1,500/microL; (3) platelets
             &gt;/=100,000/microL; (4) total bilirubin &lt;/= 1.5 mg/dl; (5) aspartate aminotransferase
             (AST or SGOT) and/or alanine aminotransferase (ALT or SGPT) (SGPT) &lt;/= 2.5 *
             institutional upper limits of normal (uln), or &lt;/= 5 * uln if liver metastasis exists;
             (6) creatinine clearance (calculated by the Cockcroft-Gault formula) &gt;/= 45 mL/min

          -  Patients must have recovered from any effects of surgery and/or radiation therapy and
             be free of significant detectable infection.

          -  Female patients of childbearing potential must have a normal plasma beta human
             chorionic gonadotropin (bHCG) within 24 hours prior to enrolling in the study.
             Patients with an elevated bHCG will undergo appropriate evaluation to rule out
             pregnancy (ie referral to OB-Gyn service, ultrasound) and if pregnancy is ruled out
             and elevated bHCG is determined to be of tumor origin, patients will be permitted to
             proceed on study.

          -  Patients of child fathering or childbearing potential must agree to practice a form of
             medically acceptable birth control while on study

          -  Patients must give written consent prior to initiation of therapy, in keeping with the
             policies of the institution. Patients with a history of major psychiatric illness must
             be judged able to fully understand the investigational nature of the study and the
             risks associated with the therapy. The only approved consent is attached to this
             protocol.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  No prior malignancy is allowed, except for non-melanoma skin cancer, in situ carcinoma
             of any site, or other cancers for which the patient has been adequately treated and
             disease free for 2 years.

          -  Patients must not have received more than 2 prior systemic therapies for RCC, but
             patients should not have received any prior chemotherapy for RCC. Chemotherapy given
             for other types of cancer more than 2 years prior to enrollment on this protocol is
             permitted.

          -  Patients must not be scheduled to receive any experimental drug for MRCC while on
             study. Patients are permitted to be on concomitant bisphosphonates or megestrol
             acetate. Patients are permitted to receive hematopoietic growth factors according to
             American Society of Clinical Oncology (ASCO) guidelines.

          -  Patients must not have had prior radiotherapy to areas of measurable disease, unless
             they have clearly progressive disease in this site, or there is measurable disease
             outside the area of prior radiation. Radiotherapy, if needed for palliation, must have
             been completed prior to enrollment on this study.

          -  Patients must not have any significant medical disease (other than the malignancy)
             that, in the opinion of the investigator, would significantly increase the risk for
             participation in this trial. Examples of exclusion: unstable angina pectoris, New York
             Heart Association (NYHA) Grade II or greater congestive heart failure, unstable
             symptomatic cardiac arrhythmias requiring medication (subjects with controlled chronic
             atrial fibrillation are eligible), myocardial infarction within the last 6 months,
             uncontrolled hypertension (blood pressure &gt;160/110 on therapy) or uncontrolled
             diabetes mellitus.

          -  Patients must not have history of other diseases, metabolic dysfunction, physical
             examination finding, or clinical laboratory finding giving reasonable suspicion of a
             disease or condition that contraindicates the use of an investigational drug or that
             might affect the interpretation of the results of the study or render the subject at
             high risk from treatment complications.

          -  Patients unwilling to participate or unable to comply with the protocol for the
             duration of the study.

          -  Inability or unwillingness to take corticosteroid, folic acid or vitamin B12
             supplementation.

          -  Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5
             day period (for short acting NSAIDs) or 8-day period (for long-lasting NSAIDs, such as
             piroxicam)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nizar M. Tannir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD . Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct;36(5):450-4. doi: 10.1097/COC.0b013e3182546a91.</citation>
    <PMID>22706175</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2007</study_first_submitted>
  <study_first_submitted_qc>June 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2007</study_first_posted>
  <results_first_submitted>April 6, 2012</results_first_submitted>
  <results_first_submitted_qc>April 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2012</results_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Non-Clear Cell</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>LY231514</keyword>
  <keyword>Alimta</keyword>
  <keyword>MTA</keyword>
  <keyword>Multitargeted Antifolate</keyword>
  <keyword>NSC-698037</keyword>
  <keyword>Gemcitabine Hydrochloride</keyword>
  <keyword>Gemzar</keyword>
  <keyword>RCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Folic Acid Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: December 13, 2005 through January 02, 2009. Participants were recruited from the UT MD Andersonâ€™s Genitourinary (GU) Cancer Center medical clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pemetrexed + Gemcitabine</title>
          <description>Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pemetrexed + Gemcitabine</title>
          <description>Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response</title>
        <description>Number of participants with complete or partial response. Response Evaluation Criteria in Solid Tumors (RECIST) of Complete Response: disappearance all target lesions; Partial Response: &gt;30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease: &gt;20% increase sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1 or &gt; new lesions; Stable Disease: Insufficient shrinkage for partial response, or insufficient increase for progressive disease, reference smallest sum LD since treatment started.</description>
        <time_frame>Baseline to 8 weeks (after 4 cycles) protocol response at 16 weeks</time_frame>
        <population>One participant did not meet the required 16 week data end point and was excluded from the response evaluation and analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed + Gemcitabine</title>
            <description>Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response</title>
          <description>Number of participants with complete or partial response. Response Evaluation Criteria in Solid Tumors (RECIST) of Complete Response: disappearance all target lesions; Partial Response: &gt;30% decrease in sum of longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease: &gt;20% increase sum of LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of 1 or &gt; new lesions; Stable Disease: Insufficient shrinkage for partial response, or insufficient increase for progressive disease, reference smallest sum LD since treatment started.</description>
          <population>One participant did not meet the required 16 week data end point and was excluded from the response evaluation and analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.2" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 Years</time_frame>
      <desc>Of the 16 participants enrolled, one participant started the study but withdrew prior to receiving any treatment and is therefore excluded from adverse event reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pemetrexed + Gemcitabine</title>
          <description>Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>thromboembolic event</sub_title>
                <description>Pulmonary embolism</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>fever (in the absence of neutropenia)</sub_title>
                <description>non-neutropenic fever</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>aspartate aminotransferase</sub_title>
                <description>AST, SGOT (serum glutamic oxaloacetic transaminase) or transaminitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>white blood cell decreased</sub_title>
                <description>leukocytopenia</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <description>Neutropenia</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <description>prolonged INR</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <description>ALT or SGPT (serum glutamic pyruvic transaminase) or transaminitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Quality Assurance Specialist</name_or_title>
      <organization>U.T. MD Anderson Cancer Center</organization>
      <phone>713-792-2830</phone>
      <email>guclinicaltrials@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

